Article Text

Download PDFPDF

5PSQ-091 Suitability of teriparatide and level of acceptance of pharmacotherapeutic recommendations in an area of health management
  1. AY Salmeron Cobos,
  2. A Rodríguez Delgado,
  3. MI Archilla Amat,
  4. MR Cantudo Cuenca,
  5. A Jiménez Morales
  1. Hospital Universitario Virgen de Las Nieves, Pharmacy, Granada, Spain


Background and Importance The use of teriparatide treatment has resulted in an increase of great economic impact at the hospital level in recent years.

Aim and Objectives To analyse the appropriateness of the prescription of teriparatide in the treatment of osteoporosis in the Orthopedic Surgery and Traumatology Service and to evaluate the degree of acceptance by the physician of the interventions performed.

Material and Methods A prospective, single-centre intervention study has been carried out between March-April 2023. Adult patients with an active prescription of teraparatide from the Orthopedic Surgery and Traumatology Service whose last dispensation was in January 2023 were included. The variables collected were: age, sex, treatment duration, dosing regimen, previous fracture and type of fracture, previous treatment, contraindications, osteoporosis.

Information sources electronic prescription application Prisma®, computerised medical records Diraya® and dispensing data using MicroStrategy software.

In case of inadequacy of treatment, individualised letters were prepared for each patient and sent to the responsible medical specialists along with recommendations for teriparatide treatment. The degree of acceptance of the interventions was measured by the percentage of patients with suspension or modification of treatment after pharmaceutical intervention.

Results A total of 43 patients (76.74% women) with a median age of 76.5 years (range 30–92 years) were included. 18.60% (n=8) of patients had treatment errors, of which 62.5% (n=5) due to dosing regimen >2 years, 12.5% (n=1) due to an error in the regimen and 25% (n=2) due to contraindications. In addition, 13 were prescriptions with a previous non-vertebral fracture, where 84.61% (n=11) were first-line teriparatide treatments, when it is not recommended. The degree of acceptance by the specialists after the intervention was 62.5%. The prescriber’s modifications were suspension of teriparatide treatment for > 2 years and initiation of bisphosphonates, modification of the regimen error, and replacement of drugs that had contraindications with first-line drugs.

Conclusion and Relevance Although there are not many errors in the treatment in active prescriptions of teriparatide, the interventions carried out were partly accepted by physicians, but they continue being prescribed as first-line treatments when it is not recommended. In addition, prescription errors were reduced and medication safety increased, reflecting the importance of the role of the pharmacist at the hospital level.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.